Ianalumab

Ianalumab (INN;^[1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus.^[2]^[3]^[4]

This drug is being developed by Novartis. As of 2021, ianalumab is undergoing Phase II/III trials.^[5]^[6]

References[]

^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
^ "Ianalumab - MorphoSys/Novartis". AdisInsight. Springer Nature Switzerland AG.
^ van den Hoogen LL, van Laar JM (February 2020). "Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome". Best Practice & Research. Clinical Rheumatology. 34 (1): 101485. doi:10.1016/j.berh.2020.101485. PMID 32067925.
^ Narain S, Berman N, Furie R (November 2020). "Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis". Current Opinion in Rheumatology. 32 (6): 609–616. doi:10.1097/BOR.0000000000000754. PMID 33002950.
^ Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
^ Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov

This monoclonal antibody–related article is a stub. You can help Wikipedia by .